Business Context and Reporting Period
This Form 8-K filing by Design Therapeutics, Inc. (DSGN) reports corporate governance changes effective June 15, 2021. The report was filed on June 7, 2021, covering events occurring on June 3, 2021.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the appointment of new directors and their compensation arrangements.
Material Changes
The Board of Directors appointed two new members to the Board of Directors:
- Heather Behanna, Ph.D.: Appointed as a Class I director with a term expiring at the 2022 annual meeting.
- Deepa Prasad: Appointed as a Class II director with a term expiring at the 2023 annual meeting. She also replaced Stella Xu, Ph.D., as a member of the Audit Committee.
Compensation and Governance Details
Under the Company's compensation policy for non-employee directors, the following arrangements were established for the new appointees:
- Annual Cash Retainer: Both Dr. Behanna and Ms. Prasad will receive $35,000 annually for Board service. Ms. Prasad will receive an additional $7,500 annually for Audit Committee service.
- Initial Option Grants: Both directors were granted options to purchase 30,000 shares of common stock, vesting monthly over three years.
- Future Grants: The policy provides for automatic annual option grants of 15,000 shares at each annual meeting, vesting over 12 months.
- Change in Control: All option grants vest in full upon a change in control, provided the directors remain in continuous service immediately prior to the event.
For 2021, cash retainers are pro-rated based on the appointment date. No other transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the effective date of the new directors' terms (June 15, 2021) against the Company's proxy statement or subsequent filings.
- Confirm the total number of outstanding options granted to Dr. Behanna and Ms. Prasad in future equity compensation reports.
- Review the Company's 2021 Equity Incentive Plan to understand the specific definition of "change in control" triggering accelerated vesting.
- Check subsequent filings for the pro-rated cash compensation paid to the new directors for the remainder of 2021.